Delivery Order SPE2DB25D3005-SPE2DB25FQHQA
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $71,609.11 for Descovy 200-25 mg tablets (30-count units) under a firm fixed price contract. This non-set-aside award, effective August 1, 2025 with an ultimate completion date of August 4, 2025, represents a pharmaceutical supply delivery to support federal medical procurement needs. The delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units, with a contract ceiling value of $21,872.95. This competitively awarded, firm fixed-price delivery order is set to be completed by July 24, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, valued at $43,062.06 for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This firm fixed price delivery order, with an ultimate completion date of July 31, 2025, represents a non-set-aside competitive award to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $34,386.90 to AmerisourceBergen Drug Corp for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This firm fixed price, competitively awarded delivery order was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a child contract under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $44,543.69 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a $20,176.14 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 30, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The contract contains no set-aside designation, reflecting AmerisourceBergen's qualification to compete in open federal procurement....
- The Defense Logistics Agency awarded a $14,582.36 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price, non-set-aside contract with a completion date of July 31, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Descovy is an antiretroviral medication used in HIV prevention and treatment, and this delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $7,539.97 to AmerisourceBergen Drug Corp for supply of Descovy 200-25 mg tablets (30-count units). This non-competitive, firm fixed-price delivery order was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Descovy 200-25 mg tablets in a 30-count unit configuration, valued at $8,022.27. This firm fixed price delivery order was competitively awarded with no set-aside designation and is scheduled for completion by July 22, 2025. The contract reflects AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran healthcare systems, with performance occurring at the company's...
- The Defense Logistics Agency awarded a $20,861.79 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price contract with no set-aside designation, competitively awarded to support federal pharmaceutical procurement needs. The work is scheduled for completion by August 1, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB25FQHQADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $13,660.97 to AmerisourceBergen Drug Corp for the supply of Descovy 200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was issued on August 5, 2025, with an ultimate completion date of August 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply agreement running through December 2026 that provides comprehensive global pharmaceutical and medical supply support to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to deliver diverse pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for Descovy, an antiretroviral medication, exemplifies the company's role in supporting Defense Health Agency and other federal healthcare system requirements through the DLA's Pharmaceutical Prime Vendor program, which the agency is modernizing through Generation V regional contracting arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.7k | 8/5/25 |